Navigating the Complexities of NASH Development: Valuable Insights From a Key Opinion Leader, New Webinar Hosted by Xtalks
The race is on for non-alcoholic steatohepatitis (NASH) drug development as the disease—which has no approved treatments—is rapidly growing in prevalence and is the fastest rising cause of liver transplantation in the United States.
TORONTO, April 5, 2018 (Newswire.com) - This untapped market and pathophysiology of NASH, which lends itself to pharmacological manipulation at multiple pathways, have prompted many pharmaceutical and biotechnology companies to pursue novel treatments to address this unmet medical need.
NASH drug development presents distinct challenges. For progress to be made, companies need to understand, formulate and improve strategies to overcome these challenges including limited education and awareness in both physicians and patients, differences in Western and Eastern populations, the presence of comorbidities, diagnostics for patient selection, and selection of appropriate endpoints throughout development.
In this live webinar, medical and operations experts from Medpace Piotr Krzeski, MD, PhD, FFPM, Senior Medical Director of Medical Affairs and Jen Harness, BS, RD, Director of Clinical Trial Management, will facilitate a Q&A session with Dr. Stephen A. Harrison, MD, Gastroenterologist/Hepatologist and Medical Director at Pinnacle Clinical Research and an experienced Key Opinion Leader (KOL) in NASH. The presenters will participate in an in-depth discussion on selected topics associated with NASH development as well as strategies and opportunities for researchers. Key questions that will be addressed include:
· What are the current trends in successful NASH trial recruitment?
· How can differences in epidemiology and patient management paradigms in the US vs Europe be leveraged to improve recruitment?
· How can differences in NASH between Western and Eastern population reflect on patients’ suitability in early/late NASH trials?
Imaging and Liquid Biomarkers
· What are the most successful current biomarkers in NASH clinical trials?
· What endpoints should be considered at different stages of development in Phase II-IV trials?
Dr. Harrison and the Medpace team will also be taking questions during the live presentation. Join this free interactive and informative session on Thursday, April 19, 2018, at 11:30 a.m. EDT (4:30 p.m. BST/UK).
For more information about this complimentary webinar visit: Navigating the Complexities of NASH Development: Valuable Insights from a Key Opinion Leader
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical and biotech companies, private and academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx
Tel: +1 (416) 977-6555 ext 352